Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Designation Requests To Get Slower Reviews

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.


Related Content

US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
US FDA Doesn't Support Creating Ultra-Orphan Designation
Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
'Cures' vs Funding: FDA Appropriations Bill Is Latest Battleground
Priority Review Vouchers Could Be Used Frequently Next Year
Targeted Therapies On FDA’s Orphan Designation Radar
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts